Klaus Breiner
Founder of Pureos Partners AG
Klaus Breiner
Founder of Pureos Partners AG
Freienbach, Schwyz
Overview
Work Experience
Co-founder and Managing Director
2021 - Current
We are an independent Swiss VC Firm. Our Pureos Bioventures funds focus on private biotech companies in Switzerland and broader Europe developing innovative drugs for severe diseases.
Non-executive Director
2021
Managing Partner
2017
BB Pureos Bioventures is a new venture capital franchise to exclusively invest in private innovative drug development companies with a special emphasis on the next generation of biological drugs and drug formats. For Pureos, we have assembled a new team of venture managers, biotech founders, scientists and big pharma & biotech executives, with long-standing experience in biologic drug development, company building and healthcare investing, and a wide-spanning network. We started Pureos as a joint venture with the Bellevue Group, which has a long tradition of healthcare investing, and is one of the largest and most experienced healthcare investors worldwide.
Partner
2004
Selected Investments: Alpex Pharma SA (secondary sale), AM-Pharma BV, Cadence Pharmaceuticals, Inc. (later publicly listed, subsequently acquired by Mallinckrodt), Neose Technologies, Inc. (asset acquisition), Orthocon Inc.(later merged to become AbyRx Inc.), Vaximm AG
Co-Founder & Vice-Chairman (Executive Chairman till mid-2016)
2008 - 2022
Board Director
2006 - 2021
ORTHOCON is a medical therapeutics company developing absorbable products for orthopaedic and spine surgeries.
Raised $47,500,000.00 from ProQuest Investments and Canaan Partners.
Senior Adviser Private Equity
2004 - 2021
Board Director
2007 - 2020
Board Director
2011 - 2019
Board Director
2007 - 2011
Education
Ph.D. (Dr.rer.nat.)
1995 - 1998
Master of Arts (M.A.)
1994 - 1995
Diplom Ingenieur
1990 - 1993